Ali Tabarroki

Author PubWeight™ 9.36^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.	Blood	2012	2.51
2	Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.	Clin Cancer Res	2013	2.00
3	Prognosis of acute renal failure in children.	Pediatr Nephrol	2006	0.89
4	SF3B1 mutations are infrequently found in non-myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype.	Haematologica	2013	0.87
5	Clinicopathologic and molecular characterization of myeloid neoplasms harboring isochromosome 17(q10).	Am J Hematol	2014	0.83
6	Short-term and long-term outcome of hemolytic uremic syndrome in Iranian children.	J Nephrol	2008	0.82
7	Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine.	Leuk Lymphoma	2013	0.77
8	Screening for SF3B1 mutations is a useful tool to differentiate between acquired clonal and non-clonal sideroblastic anemia.	Leuk Lymphoma	2014	0.75
9	Spontaneous recovery of severe nilotinib-induced bone marrow aplasia and successful retreatment with dasatinib in a patient with Chronic Phase Chronic Myeloid Leukemia.	Leuk Lymphoma	2014	0.75